PT  - JOURNAL ARTICLE
AU  - Hannatu Tunga-Lergo
TI  - Developing a Community Engaged Sickle Cell Disease Center: An Initial Data Analysis of Healthcare Utilization Rates and Perspectives of Key Informants
AID  - 10.1101/2021.04.07.21254482
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.07.21254482
4099  - http://medrxiv.org/content/early/2021/04/10/2021.04.07.21254482.short
4100  - http://medrxiv.org/content/early/2021/04/10/2021.04.07.21254482.full
AB  - Background The mortality rate of individuals with Sickle cell disease (SCD), the most prevalent genetic disease in the United States, has been increasing at 1% per year. It has been declared a global and national public health priority by the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC). As a complex chronic and acute condition, preventive care and patient management of SCD requires a patient-centered, comprehensive, and multidisciplinary approach; unfortunately, few SCD treatment centers use this approach. Moreover, individuals with SCD are at the intersectionality of race and socioeconomics and thus face additional barriers to access to quality care, which may ultimately result in higher utilization of acute care services, especially during the transitioning period from pediatric to adult care. Greater acute care utilization has been found to be associated with higher mortality rate and severely compromised health related quality of life; thus, it is important to assessing needs of SCD patients as they relate to access to quality care.Objective The aim of this study was to conduct a preliminary needs assessment for the development of a community engaged SCD center. This study also aimed to determine if frequency of acute care utilization was associated with age and insurance type, to provide surveillance data, and to identify opportunities to address barriers to access to quality care from key informant (local and cross-institutional) perspectives.Method A retrospective cohort study of SCD related emergency department (ED), inpatient hospitalization, and outpatient clinic utilization encounters, which occurred from 09/01/2012-06/01/2019, was queried from UF Health’s Integrated Data Repository (IDR). Quantitative analysis, frequencies, proportions, and Pearson Chi-square inference were conducted on the administrative data received. Further, key informant interviews of stakeholders in Alachua County, FL and Yale New Haven Health’s Adult Sickle Cell Program, New Haven, CT were performed. An iterative qualitative thematic analysis of their perspectives was conducted.Result There were 27,932 total encounters that were stratified by age and payer type. The average length of hospitalization stay was .71 ± 3.84. The 18-30-year-olds had the highest proportion of ED utilization (34.7%), hospitalizations (32.1%), and outpatient clinic utilization (26.4%). This was followed by the 31-45-year-olds with 20.4% of ED utilizations, 22% of hospitalizations, and 20.5% of outpatient clinic utilizations. Those with public health insurance accounted for 74% of ED encounters, 81% of hospitalizations, and 82% of outpatient encounters. Common themes and subthemes from key informant interviews included: champion, transition of care, pain management, bias, patient and family education, provider knowledge, social worker, multidisciplinary/comprehensive care, mental health, education, and employment.Conclusion Among adults with SCD in the UF Health system, younger adults (e.g., those who are transitioning into adult care) and those with public insurance utilized acute care services at greater proportions, indicating a need to identify and address possible barriers to access to quality care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Florida Institutional Review Board Gainesville Health Science Center/Jacksonville Health Science Center (IRB-01) Committee. Approved.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSecondary data sets available through University of Florida's Integrated Data Repository. Anonymized primary data set available from researcher. https://idr.ufhealth.org/